THY1 and hepatocellular carcinoma: Additionally, it was observed by Rani and colleagues that treatment with Galunisertib in vitro modulates the expression of stemness-related genes in invasive HCC cells (HLE and HLF) reducing the expression of CD44 and THY1 and consequently results in decrease in colony formation, liver spheroids and invasive growth capacity in vitro and in ex vivo human HCC samples [24,25].